“Effect of Hormone Resistance Type on First-Line Treatment Selection in ER+/HER2-Negative Metastatic Breast Cancer” (2026) Voprosy onkologii, 72(3), p. OF-2675. doi:10.37469/0507-3758-2026-72-3-OF-2675.